N
Google TrendLAMINE YAMAL (5000+) — "You want to play for Morocco?": Getafe defender provokes Yamal with shocking words
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lamine yamal5000+thélyson orélien500+adeyemi500+abdulrahman alfozan500+pope francis500+delaware vs middle tennessee prediction500+bayern de múnich200+pablo torre200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "MRD Negativity Is Sustain" (30 stories)

Top Headline Story

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
Lead StoryOncLivetech
Jul 3

Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPbGtlSUNtNnFHem81enRPNVQ1RGlkM2RsNU1mc3NhaGZfSEJjSXRQRG9ib3F0MmxwMkh3NkhWMy1JSXd3bDhDb2FzOEN3OGpQTFBzNU5DRktfMHY0YkhVQXY2UXJXUjhPWmU5MEpucHpZV1dNV3FsbzRFV3FJQlprbEk3MHFBNVA2T0VJMXptcVMxQWNzTUZyNndVOE0?oc=5" target="_blank">Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+27m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+27m ago

thélyson orélien

Acclaimed Author Denies Using A.I. but Admits Plagiarism

Filter stories
500+27m ago

adeyemi

Licensable picture: Galatasaray v Barcelona - UEFA Champions League

Filter stories
500+37m ago

abdulrahman alfozan

Saudi national OpenAI employee arrested after 'sophisticated recording device' planted in office

Filter stories

Search Results for "MRD Negativity Is Sustain"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma
Targeted Oncologytech

Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQTjhGTDNEY2FDNnd4aV8zeVFPOVktOHpaMGNMWDZZS2d0Vk1CclVSOVNDR090aFJNRVhrSnRpb19XdHRfd084UFcxMG00dFptODJWZk9xYU5HU0dWZmlQaVVidkZsT2dHZnZpMjV4dDU4Wk5CVVNGUTk4eVJCbU1FZUQ5ak9pU3lrMDR1eXdVVmFrdXhjZnFyc1hvMDhpUHMxby1NLXR6MTVsaXRIZXc?oc=5" target="_blank">Isa-VRd Sustains and Deepens MRD Negativity in Transplant-Ineligible Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Sustained MRD Negativity Predicts Long-Term Outcomes in Multiple Myeloma
HMP Global Learning Networktech

Sustained MRD Negativity Predicts Long-Term Outcomes in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPNVVudG5pZVhMZ2RFTnI4Sy1VRzVZN0MwZkJBdWZoUUN0aG5CVkl0aUdrUTFRSUpsZ05JUWJ2ZHc5WmszcHpIaVR5U2h6SFpFQVVBdzJHYTUtMUJYRE1Za0Jvb25hYVNhMl9ZSHNNX0djZklhS0xiQjJyOFR4VVVvczFTRWh5NkVfLUtfNUx6SzhucllQemNwckFDdjBQV2dOM2VUazJtOHpiZVd5cEhxZlFnNjA1WkloYVpGRUFJUUwzbndP?oc=5" target="_blank">Sustained MRD Negativity Predicts Long-Term Outcomes in Multiple Myeloma</a>  <font color="#6f6f6f">HMP Global Learning Network</font>

Read Full StoryMore like this
Can Isa-VRd Sustain MM Minimal Residual Disease Negativity?
Medscapetech

Can Isa-VRd Sustain MM Minimal Residual Disease Negativity?

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxPY19INU9XTHFjVk9NdHRtVzYwal91WVVkZHJyWG5BcFpoaXZ3ajBMT3J1T28xdXpOX0ZEWWxSWW1uYTAzak10VWhqS25BSFZPazk1NE9JclBjdVNxb0c2dDJUcEpwdC1JX1FKX1YwSkY1QVhaLVEtdjd5dVZDclFQRVRhSGU4WEw4ODk3NWN1UzIwYWcyM2Y4R3REZGozbko2R1RjLTlB?oc=5" target="_blank">Can Isa-VRd Sustain MM Minimal Residual Disease Negativity?</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma
CancerNetworkgeneral

Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQdXdROUdnRjNGcmJNc25hMW50blNDRW05TU5xOXhLMVR2SUJvaEpHNjBPMnpUbklBVGROTTNXU1VpcC02aGJ0WUhqc1laZjVpSG9ZUWJibG1uY2FKUTI2WElIak1VVW5tSF84RjI4UDk1STBPd1VtRTNlekpFSnVLT3lLMTRURUU1NWFrQzlZalEzMG52QUZMdlJCZ3htb2RwN3R3NGJ5emRZSGhwMzVHamVWNUVTUQ?oc=5" target="_blank">Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma
Targeted Oncologygeneral

Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQck5rOTg2eEVfWmZ0UnFIcVJCT0tOMXBrWUdnMjJmSEdaRUdtTnR2ay1FRUczb20tWDNJcmRlZkxETjVuVFNVY01ZOEZqZDdUVGgyckEtMHVIcl9YUXh1Ry10algyXy1mTWs2X3NRSnppOEV5dzJkLTREOWRUcTUwSlE5OUNTR1F5YkhrRUZRcEp4R255UU1LT3hiNVZWLVNkVlE?oc=5" target="_blank">Cilta-Cel Yields 100% MRD Negativity in High-Risk Smoldering Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
Naturetech

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBvdGFONXNEZjFXNTJ6dnhSeWJzU3RTVU1fRzl1Z21yaTZ5dndNNmJVLXRubUs5ZUJhLUpGek9TcWxhSTlvemc3aV8yUmtQNmdBV3J1cFhaNzZUZU04NmZZ?oc=5" target="_blank">Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
OncLivetech

CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxPX21zRldISHptSi13RVB5QWQ2V2VOMmFEY1hZQzFIXzhwNk5HTXhFWi1uT2tHSHZSR2pTOHlRTXFJa3FJdlpGZmVwal9Qa1pRSmhEcGFmZVA1c2c3dFZ4Z0U2blFhdjZTQ1FyRGZtZnR3elZvaTRzSGdpdHFONTNJMC0xOVBVODZVUXNIdzdoaXVXSTlWRDdxY2U0d18xYjQtU2d3NElXaXkta291U3VNUmFCNDBzRmpzcFROVDNGQlZfQVZpbEUzWUpRT0lvTWJhSkNpemppQzA?oc=5" target="_blank">CEPHEUS Final Analysis: DVRd Sustains Efficacy Benefits in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Belantamab Mafodotin Combo Sustains MRD Negativity/PFS in Multiple Myeloma
CancerNetworktech

Belantamab Mafodotin Combo Sustains MRD Negativity/PFS in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNY1BqeVY2SmVmZFlFYnZlUGZHazktWVRIa2VlZnh0UEVRUjd0Z1hoMFNYODhlRU1FZENCdGlGMlBOTUFMT0h4ZGN6bFNYWnotcXFwTWdXLXdYZ3dBNTBnV21mNGMtSU9URDlGc3JHNjI5OGVaWW4tV1BSVjlTTm5La3N0VVRJTFpseHN4QmNmNDh0bnRSYUh2M0lqWmJBbVFGaHNjUEVGNk56eWplSGc?oc=5" target="_blank">Belantamab Mafodotin Combo Sustains MRD Negativity/PFS in Multiple Myeloma</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients
Oncology News Centraltech

Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPN1pUZk9hX1lrcmNadGY1WVdHQUM2eTlSZWxXcnhpaGQyVWtsdXBObUxaMndnU0p2ZnhtWkVjVHRFLTRtMjY2T0t5MTM2WkVJUVp2S3FKZzV2SjZqZ09jWmJVV0RiTmI3SVMzUmlHdFVKaXhpS2lPRUpnSUxMYUlraVNaZnEwS0N2cUtOR1FvUzBUWDNEaGUzZVpMNHl0elJUQ3FxYUVQYkpscVNxdDVFcHpRQ3U5Mkd4VXQ5b2NXVEVwYVJva2hYTW16UnNFcHRLVGc?oc=5" target="_blank">Myeloma Quadruplet Doubles Sustained MRD Negativity in Transplant-Eligible Patients</a>  <font color="#6f6f6f">Oncology News Central</font>

Read Full StoryMore like this
Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma
The ASCO Posttech

Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOSXFCbFRKdXFlU2VQNjczc2tyczZHcTNyVUpNR0d5TkdrNWY3T3EyYVV3ejlzRFdhanVNRVB6THVlVnRjaDNYMnlDSFZEaUhZUkdjUE9HcjZBRkdMSDB0MlU5Y2FSYmd0Mk1pTEVPZWdsLW53NkFBMVpzQU85bWN3aDNzUUxOaElRRmczOERNbVVQZzIzN3pvd0EwaG5lbDhYUHlkY3lxcFlGWTBpUDk4WE0tdnZUUGRwMXpnQ3NFOTJ6c2QyS1lN?oc=5" target="_blank">Sustained MRD Negativity Achieved With Isa-KRd in Newly Diagnosed Multiple Myeloma</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)
OncLivetech

Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)

<a href="https://news.google.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?oc=5" target="_blank">Sustained minimal residual disease in BENEFIT phase 3 randomized study of Isatuximab plus Lenalidomide and Dexamethasone with Bortezomib (Isa-VRd) versus IsaRd in newly diagnosed transplant ineligible Multiple Myeloma (IFM 2020-05)</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma
Targeted Oncologytech

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNdVo2WGhIMlBsV3BuTHdYaVNhWW1UcTFiRjJ2Rmt2RWsxbzY4QlZwNExaUU93ZURCX1FnN2dTcVVmeHhfM0lZME9UOXZlRE8zc1R0WEszc1dyTUkzR2p3Z0NHcGw3aHJSQ212QmllNmVUdVdrcVFZMnQzcFFRUmhnMkQ1dDhtT0dtbU9NSEVRcHNVZGZrcUN2MnVER3g5aGRhcWZORlhLSUJZUFoxMnVEckVR?oc=5" target="_blank">Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM
CancerNetworktech

Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxORmNyU1poRHhCQzduZVZlRkRZUkNUa29ueVFLd2U4ZTNaUjNXdy1kRmV0Nmg5UkJpNW40Szd3RnVFdk1vZkFzN0JDTXZvSHJ0SFpuVXk2QVVTRWlkX0p5UDM2by1LWHhvS3BHZE51WjBseHRkMXdJRGZoWG1NTzR3QWhWYkZjRllWYVBmRHBaSll0NTZzYjhvalFMemh4ZG1FamJYcg?oc=5" target="_blank">Subcutaneous Daratumumab Combo Sustains MRD-Negative Status in NDMM</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy
Targeted Oncologytech

Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPZ00weFVmR00zUktRT1RnUVF1aHlXdVdPN1Jrd2lqUE1heWxHYzNCRG1QNUctMm5XcEtfVlY5c0R3T3J1WnBsQmVnX3FzOW5VSkN3TEkwSVZLT0RwMVVWUkhBcjVud2VBaG1PdmdMVUFjTXVZTVI2RXNRTXBjNFRVZ0hHemNKeFFaeDRhcHhqM0dzYWxzT3JtYldtbUpzaWFx?oc=5" target="_blank">Measuring Sustained MRD Provides Path to Tailoring Myeloma Therapy</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma
OncLivetech

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOVDFvVlBST1pjWHl2Y0pOQVgxZURGbFBGd3J1NjQ3OS1CWFRXOU9sNE5DTkF5Vk1RNVpHVk05Wm54NVdjTmlGZHlNQmE5b2p2dnY5WVp2Q2NqYmk1cC01NHRIVnA4dFQzWXVnMHMzaFptQlpRTnM5bkZHUi12MmlNb2NuZnVib0tReWc5YXhBZkZDUWNaV1VGb25zZWd1T1haSW1tLXRyc0RlSldVdlZPSFJEdnhPUUVoRW82eg?oc=5" target="_blank">MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Dara-VRd Leads to Sustained MRD Negativity in Newly Diagnosed Myeloma
Targeted Oncologytech

Dara-VRd Leads to Sustained MRD Negativity in Newly Diagnosed Myeloma

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxObEhkeWZWTWp5M2NEY0g2aldIYkVjQ2Nnd0pHYmZGY19YcWNKZGVPbWEwMlJmQ1c0bjlzalJPRUo5NU1SR1VNelVtejBrUUhsazJZY2JBNjZRdW9EYmFzeDFfM1RPdWRfMXZNMDhEdE90NXQ1SXJwU1ItYm9nNFNQRW0yQk5vTWhaOUJUWll5YUtzXzRmcndiTXNGcS1iMG9qdmVyOQ?oc=5" target="_blank">Dara-VRd Leads to Sustained MRD Negativity in Newly Diagnosed Myeloma</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma
OncLivegeneral

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPeFM3QlFaMDZEWE1JcjBjeG1FdDVQOFZ3Vy1fWTNNNldUREg0bDBRdnQwVDBBdVQxM2tvbGRlUG9EV1NKMlZEVkhsWTJnUE8xd2V1UnBXNkNaaHAtSGlZemhaVklaRFA3N3RwUGIyQlJfaDJ0RjE2YVp0a1JzVVVjRllnWDYxUkw5SldhSGJPbFJSOFlQM2ZtanJxTDVtaERuT3ZkVWpwN2M4SWpjTVE?oc=5" target="_blank">D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma
OncLivegeneral

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPejdfcG5xcmJOVDd6RHZFcVpUVG5iaURCY0JaUDhTRWY4bmdjS3BFRHB0ZV85a3o3anRMbmxYVmwtcjhBR1hxWW1YMFEya3BqNUpsUnA3T3RXWkNvWks1TGdiZ2NHRndRWW5ZcXo3dkFTV1gtOTRoMmZuTDVWMmVaZ2h5MkUwaGZEc2Y2RUxjRlZXeGdxSE5ic0xqTGRMZkJKMTBlQVBMN3U0TGJpZXBYeQ?oc=5" target="_blank">Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM
CancerNetworkgeneral

Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNRWJzNTMycU10RXRtanpacWdIWlhGMTFWSGZNU2ZOQmdfb1NsbU9jYnFHZU9GMEVES1BHdkFJUENzdjRUX1hfaXhaR2ZlTERUS1hyajBPc29mWmliejRPQzdDUjAxN0hiVmZxT1NqbUFDNlNlS1RsVG1sZlRBZ09zMlBCb1RabVNrNlFQYzEteEM0eWlfSUJLYVFwVFRjRGIySjJqMWE2aE0?oc=5" target="_blank">Isatuximab Regimen Improves MRD Negativity in Transplant-Eligible NDMM</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
AACR 2026: 100% MRD-negativity rate achieved for high-risk smoldering multiple myeloma
Oncology Centralgeneral

AACR 2026: 100% MRD-negativity rate achieved for high-risk smoldering multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQME40Mlh4ZXllNmNMOERvbkp6N3FJeGROOTMtUkwzZEpfM2Rna0JxNDNIN2gxUW9Gb3hEMWdLMEpTbjdFNEd4UEZJZWMteGdzSjctX2c2M2xoR1FqZWNEaHhQcUN0M0cta1NXTV9aTG9FQV9DOVItZTRWOHpBUEtkeFNoYW9KVVpadlhDNUVzVTdsRldUc0toa2xkN2daX3pTdGF1S0F3c29vTXlFZjFqSEM3eEpsemtIM3c?oc=5" target="_blank">AACR 2026: 100% MRD-negativity rate achieved for high-risk smoldering multiple myeloma</a>  <font color="#6f6f6f">Oncology Central</font>

Read Full StoryMore like this
Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma
OncLivetech

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOdUVyMXBmNHp2Ykl4R3JKX0lmaktwbkI1eE83ZUNuRmFNUFlONmlwOE83aVhyblFmZjM1UjlCb0NRdTNMZkktdmdEaWFIOThJcEh2akM3T3lZNHZidFFwbUkzTWxsSzdIczVEZ2Q5TEFsUFRRWVNCX1hvNFBfcWRVcm5rSDVTUGNZQWhzSTVSZWxadUZWUUNMRGpIOXlpNGc?oc=5" target="_blank">Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
Isatuximab Boosts MRD Negativity in Multiple Myeloma
Medscapegeneral

Isatuximab Boosts MRD Negativity in Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOSXlFdXdGMG1vZnpkVDFXaGc4TDJxTU8ySWduUkZDclFXa0VOVWJaZ2pJeE9PYmtMUFBnbDc0QThOa25HYjhhMnJrSkcxQktzeWstUF9lVkFFVm4xbDJ6X3Mwejk4ZnRaUDd1enUzOWZhSTN2OWNVUk5BZW9iRm9uS3ktQ29aT3J4elBBeGlFNVhfWVQ5d0dVdUNLeHpiTXVr?oc=5" target="_blank">Isatuximab Boosts MRD Negativity in Multiple Myeloma</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
MRD End Point Brings “Positive Change” to Multiple Myeloma Research
CancerNetworkgeneral

MRD End Point Brings “Positive Change” to Multiple Myeloma Research

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNU1NMdDZUSzhHOTc3b0gzQjRMekR0V1FKUHFMVDJwN0o3WUh0LWxma20zZHZidkcxQUIwQ3ZTU1VzZVVIV1lmMlM4WHcwVTVieHhKbGZhM2duZlVyUkUyMkV5MHlCdlZpQ09vU1I4X3BxNmxLRE1ISnZKUEZHMUlLX3dlVlNYNlZHRDhJZjNkeEp2MUxTZW9TbzIzMU1HX0sycmc?oc=5" target="_blank">MRD End Point Brings “Positive Change” to Multiple Myeloma Research</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
Targeted Oncologygeneral

IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxONDVHYTl2dlh1NlF1TVVlSS0xOXNJRk82N0RNa2VJck14ZVhPdlpJRjJkRWQxeERaanZzSTdKLXlSaHZ5eFlKOWMzZU8wNGViQzlZc1FnNEhfY29jeDJ5bU9fMnplYy1PWkp2SlZPcGVYRTJmNXFNY3RPWlBLSFFtYTBuYmd0aEdGOGJvS0Z4MGw5bUk?oc=5" target="_blank">IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions</a>  <font color="#6f6f6f">Targeted Oncology</font>

Read Full StoryMore like this
Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma
OncLivetech

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOMXo0U0pITnpBaW1YOGJXX0REREpxZnhzSXVGOXpyMUpfVWtKMHlUSGNVX042Y0o0enNvS3dqVnZOaGg5WjN0WkdOeVF1SXZ5bmRJTVZ4UmVPQy1GVkNnQTVuSi1URllmZkxXcHUxMkZVVHBTUU85Sno5SWc1TWE1MGtDNmQ5M1NPVkZGZ0w0OHdITkQtZHkybjhCNHZsbkJfYWpNSDVMMDhfMjduelg5QmRwSjc?oc=5" target="_blank">Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
CEPHEUS Trial Data Reinforce DVRd as New Standard for Multiple Myeloma: Saad Z. Usmani, MD, MBA
AJMCgeneral

CEPHEUS Trial Data Reinforce DVRd as New Standard for Multiple Myeloma: Saad Z. Usmani, MD, MBA

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNM09qTkZjMDV1RmExVlFtdHYwOWdON3ppeUg3TEZVcnl0eTA4anZ6MmFwdUUzWTVNeTU3VnZUR1pscC11X1k1WmZzT2xIQ3pYdlU1OXlyb1I3RmJGTzN2Q19wZkVxTk5ZdDV0TjhyVHJSVFZmTllVeEREdThMLU1uWWZleDFKUXNSWVludzJLM05FYmphOTY0WlJ0Nll2QWczOE10WjAxVDZWUVhFOVFabkJMeUVJRlJm?oc=5" target="_blank">CEPHEUS Trial Data Reinforce DVRd as New Standard for Multiple Myeloma: Saad Z. Usmani, MD, MBA</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM
Hematology Advisorgeneral

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPYzM1ZmdoNDFfWEdWZzdSeTdqaHFaNXJXVGxfdjl1QWdMRWg4TkVzUUZzanplUWVyWDZ5eFQyY1NzM2RaVzZlZGNocmlyaFNqNGljQjNqeFloMzFPOEtVUEozT2Nsd3F0bGR0akgwXzZtM0p5R3lzRTJyMkItOVBfZHoyOVU0S1U0QWtaT1JndGVfR01Ud2I3emlhNmpSNy1CdUtaT1VXYWM?oc=5" target="_blank">AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM</a>  <font color="#6f6f6f">Hematology Advisor</font>

Read Full StoryMore like this
Daratumumab Plus VRd Yields Sustained MRD-Negativity Regardless of Cytogenetic Risk Status in NDMM
Pharmacy Timestech

Daratumumab Plus VRd Yields Sustained MRD-Negativity Regardless of Cytogenetic Risk Status in NDMM

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPR3JZWUQ4WnpmOWNINDlaaUl4V29MaHlxVlAzUzFaR0dPTzhKdVZma3hUZFdfUVhzb3ZXdndZN09kU0JnbGdsN0p3Zko2dzRBSUsteFhqVUQ1RWVmWG5nRUlzZzdQQzl3a1ZmeWRGZmJPRk0tWVgxSkw3ck1ZS3liYmhiYVc5Nm84WGNRRGg1UGRFcGV0cjZlaUFxLTlVSGZodzJ6cEdhUXAyLWp1MGgxTzVkTXdhWGRzX3RxUVRpUUdJUllub3lhMFZvTXBWZw?oc=5" target="_blank">Daratumumab Plus VRd Yields Sustained MRD-Negativity Regardless of Cytogenetic Risk Status in NDMM</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma
OncLivegeneral

Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNRTRXWlRFR2ZSZXZCMlMyR1VBMHJfaW9fZ3kwQVZXZGhBZ0t3Y0p3S2twS0ZZdTZ5RktyckxrdVRVaDJ0ak5zdVdBR0FTOXZNdlBuNXBWSVUzbkdIdzRrazdvakNBUXpDNEx6XzUtdnJqMGsyY28tQ0pwd2JKSnEwUWFmSFp1bGR5OU5FT0FneEVYTDRpZEMzOHdTbmhhVjN2NFZDbjlQV0Rrc1cxQUo4?oc=5" target="_blank">Anito-Cel Yields Durable Responses With Manageable Safety in R/R Multiple Myeloma</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
"MRD Negativity Is Sustain" — Live Google News Trends & Headlines